Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Regulatory News In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Repeal that regulation!

You may also be interested in...



Agencies Launch White House-Mandated Review Of Regulations

FDA and CMS announced preliminary plans May 26 for updating, streamlining or eliminating certain regulations in response to a White House request.

Agencies Launch White House-Mandated Review Of Regulations

FDA and CMS announced preliminary plans May 26 for updating, streamlining or eliminating certain regulations in response to a White House request.

Device Innovation: Report Paints Dire Picture; Prez, FDA Take "Positive" Steps

Last week started off with a particularly negative appraisal for the prospects of continued U.S. leadership in medical device innovation under current policies, but it was followed by two developments that almost appeared as corrective responses by the federal government.

Table

View full table

Tags:
Latest Headlines

Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

See All
UsernamePublicRestriction

Register

MT030099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By